The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins

Chronic myeloid leukemia (CML) is a clonal malignant disease caused by the expression of BCR/ABL. MDM2 (human homolog of the murine double minute-2) inhibitors such as Nutlin-3 have been shown to induce apoptosis in a p53-dependent manner in CML cells and sensitize cells to Imatinib. Here, we demons...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: You, Liangshun, Liu, Hui, Huang, Jian, Xie, Wanzhuo, Wei, Jueying, Ye, Xiujin, Qian, Wenbin
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352360/
https://ncbi.nlm.nih.gov/pubmed/27999193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13951
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items